The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
Break Apart Probe
- Order Number
- Package Size
- 100 µl
In 2008 the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues introduced a new category for myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Many of these cases present as a myeloproliferative neoplasm, usually with eosinophilia.
The 8p11 myeloproliferative syndrome (MPD) also known as stem cell leukemia-lymphoma syndrome (SCLL) is associated with translocations disrupting FGFR1. Imatinib, which induces durable responses in MPDs with PDGFRA and PDGFRB fusion genes, is inactive in patients with FGFR1 translocations.
- Chronic Myelogenous Leukemia and Myeloproliferative Neoplasms (CML/MPN)
Two green-orange fusion signals (2GO).
Aberrant Cell (typical results):
One green-orange fusion signal (1GO), one green (1G), and one orange (1O) signal indicating a chromosome break in the FGFR1 locus.
- Cross et al (2002) Leukemia 16:1207-1212
- Walz et al (2005) Leukemia 19:1005-1009
- Chase et al (2007) Blood 110:3729-3734